Received May 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 793PT | — |
Intravenously administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a 54-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 793PT, expiry date 29-AUG-2027) for prophylaxis. On 27-MAY-2025, the patient received Boostrix. On 27-MAY-2025, an unknown time after receiving Boostrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Intravenously administration). The outcome of the intramuscular formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-MAY-2025 The health care professional reported that a nurse upstairs administered the Boostrix vaccine intravenously instead of intramuscularly, which led to intramuscular formulation administered by other route. Then the reporter just concern what the potential ramifications of that. The vaccine administration facility was the same as primary reporter.